Lir Life Sciences Corp (BBCMF) Stock Price, Trades & News

Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	26.31
Equity-to-Asset	0.93
Debt-to-Equity	0.03
Debt-to-EBITDA	-0.02
Piotroski F-Score	N/A/9	0 1 2 3 4 5 6 7 8 9
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	36.18
	9-Day RSI	38.55
	14-Day RSI	38.76
	3-1 Month Momentum %	-79.23
	6-1 Month Momentum %	-92.55

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	13.35
	Quick Ratio	13.35
	Cash Ratio	11.81

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Shareholder Yield %	1.59

Profitability Rank

2/10

	Name	Current	Vs Industry		Vs History
	ROE %	-473.99
	ROA %	-353.31
	ROIC %	-2311.71
	ROC (Joel Greenblatt) %	-13564.71
	ROCE %	-422.34
	Moat Score	2

GF Value Rank

	Name	Current	Vs Industry		Vs History
	PB Ratio	9.47
	Price-to-Tangible-Book	5
	EV-to-EBIT	-4.36
	EV-to-EBITDA	-4.37
	EV-to-FCF	-5.56
	Earnings Yield (Greenblatt) %	-22.94
	FCF Yield %	-18.05

GF Value™

BBCMF

Warning Signs

Warning! GuruFocus detected 2 Good signs with BBCMF. Try a 7-Day Free Trial to check it out.

Lir Life Sciences Corp Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Lir Life Sciences Corp Stock Events

Financials Calendars

	Event	Date	Price ($)
No Event Data

Guru Commentaries on OTCPK:BBCMF

No articles.

Press Release

	Subject	Date
	LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules	2026-04-28
	LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.	2026-04-20
	LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories	2026-02-05
	LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies	2026-01-29
	LIR Life Sciences Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules	2026-01-22
	LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies	2026-01-15
	LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform	2026-01-08
	LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor	2025-12-18
	LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies	2025-12-11
	Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies	2025-12-10

10/Page

Articles on Lir Life Sciences Corp

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.